XPOVIO® Now Funded in Ontario, Newfoundland and Labrador, and New Brunswick

XPOVIO® Now Funded in British Columbia

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in British Columbia as of October 1, 2023. Further details on the criteria can be found here, under the MYBSD protocol: Lymphoma & Myeloma (bccancer.bc.ca) We are excited...
XPOVIO® Now Funded in Ontario, Newfoundland and Labrador, and New Brunswick

XPOVIO® Now Funded in Saskatchewan

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Saskatchewan as of September 1st. Please see the following link for full funding criteria: Drug Formulary (saskcancer.ca). We are excited about this important milestone for...
XPOVIO® Now Funded in Ontario, Newfoundland and Labrador, and New Brunswick

XPOVIO® Now Funded in Alberta

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Alberta as of June 5, 2023. Please see the following link for full funding criteria: AHS Outpatient Cancer Drug Benefit Program 2023-06-05 (albertahealthservices.ca). We are...